Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | KIF11 | P52732 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319831 | 0.85 | HTR2A (0.56) | HTR2AHTR2CHTR2BPOLBKDM1A | |
| SCHEMBL6318787 | 0.84 | ALDH1A1 (0.43) | HTR2AHTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL25456800 | 0.79 | KIF11 (0.49) | HTR2AHTR2CHTR2BKIF11POLB | |
| SCHEMBL4773039 | 0.79 | KIF11 (0.49) | HTR2AHTR2CHTR2BKIF11POLB | |
| SCHEMBL27493841 | 0.77 | HTR2A (0.55) | HTR2AHTR2CHTR2BKIF11POLB | |
| SCHEMBL6325209 | 0.76 | HTR2C (0.51) | HTR2CKDM1AKDM4EALDH1A1HPGD | |
| SCHEMBL22878804 | 0.75 | HTR2A (0.59) | HTR2AHTR2CHTR2BOPRM1OPRD1 | |
| SCHEMBL6324914 | 0.72 | HTR2A (0.62) | HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL8098501 | 0.72 | MTNR1B (0.52) | HTR2AHTR2CHTR2BKDM1ASLC6A4 | |
| SCHEMBL8098503 | 0.72 | MTNR1B (0.52) | HTR2AHTR2CHTR2BKDM1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | HTR2A 2084/4885HTR2C 2450/4885HTR2B 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.